Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View PlansCash Conversion
0.77x
AUROPHARMA's operating cash flow covered 77% of net income in FY 2025. Some earnings may be tied up in working capital.
Free Cash Flow
₹19.57B
AUROPHARMA's free cash flow was ₹19.57B in FY 2025, up 665.8% from FY 2024.
Dividend Coverage
1,881.5x
AUROPHARMA's free cash flow covered dividends 1,881.5x in FY 2025, leaving room for reinvestment or debt reduction.
CapEx Intensity
50.1%
Capital expenditure was 50.1% of operating cash flow in FY 2025 for AUROPHARMA, a moderate level of reinvestment.
Hover the chart icon for YoY change.
| Item | Chart | 2024 | 2025 |
|---|---|---|---|
| Net Income | 43.80B | 50.66B | |
| Cash flow Operating Activities | 24.35B | 39.25B | |
| Investments in PPE | -27.80B | -19.68B | |
| Cash flow Investing Activities | -42.56B | -18.76B | |
| Dividend Paid | -2.64B | -10.40M | |
| Cash flow Financing Activities | 8.00B | 1.20B | |
| Cash at beginning of period | 43.92B | 33.85B | |
| Cash at end of period | 33.85B | 55.64B | |
| Free Cash Flow | -3.46B | 19.57B |
Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025